Is Star Imaging and Path Lab the Best Stock in Its Sector? A Look at the Numbers
- October 22, 2026
- Posted by: Kunal Singla
- Category: Market
Star Imaging and Path Lab CMP Rs 71.75 (22 Oct 2026). Market cap Rs 125 Cr. ROE 16.61%. P/E 6.49x versus Industry P/E 59.59x.
Quick Answer
Star Imaging and Path Lab is one of the names investors compare when screening the Diagnostic Services sector. Whether it is the best stock in its sector depends on whether an investor prioritises return ratios, valuation or balance sheet strength. This article sets it against two named peers and the sector benchmark so you can judge for yourself.
Is Star Imaging and Path Lab the best stock in its sector? The stock trades on the BSE at Rs 71.75 as of 22 October 2026, within its 52-week range of Rs 46.00 to Rs 152.00. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Star Imaging and Path Lab
Star Imaging and Path Lab Ltd is a Delhi based diagnostic healthcare services provider, and company information says it was incorporated in 2004. Company information says it was originally Janta X-Ray Clinic and offers pathology, radiology, cardiology and neurology services through B2C, B2B and B2G models, with NABL accredited facilities. At a market capitalisation of Rs 125 Cr, it is tracked as part of the Diagnostic Services sector on Univest.
Is Star Imaging and Path Lab the Best Stock in Its Sector?
Star Imaging and Path Lab makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, backed by its return on equity. Star Imaging and Path Lab’s 6.49x P/E is below the 59.59x Industry P/E, Dr Lal PathLabs at 59.51x and Thyrocare Technologies at 44.76x, while its 16.61% ROE is lower than Dr Lal PathLabs at 20.13% and Thyrocare Technologies at 27.85%, and its debt to equity ratio of 0.18 is above Dr Lal PathLabs at 0.08 and Thyrocare Technologies at 0.09.
| Metric | Star Imaging and Path Lab |
|---|---|
| CMP (BSE) | Rs 71.75 |
| 52-Week High / Low | Rs 152.00 / Rs 46.00 |
| Market Cap | Rs 125 Cr |
| P/E (TTM) vs Industry P/E | 6.49x vs 59.59x |
| P/B | 1.08 |
| ROE | 16.61% |
| EPS (TTM) | Rs 11.05 |
| Dividend Yield | 0.00% |
| Debt to Equity | 0.18 |
Compare Star Imaging and Path Lab Against Other Diagnostic Services Sector Stocks
How Star Imaging and Path Lab Compares Against Its Diagnostic Services Sector Peers
The table below sets Star Imaging and Path Lab against 2 other Diagnostic Services sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Star Imaging and Path Lab | 125 | 6.49 | 16.61% | 0.18 |
| Dr Lal PathLabs | 32,511 | 59.51 | 20.13% | 0.08 |
| Thyrocare Technologies | 7,873 | 44.76 | 27.85% | 0.09 |
| Peer average (2 companies) | – | 52.13 | 23.99% | 0.08 |
Measured against the peer averages, Star Imaging and Path Lab’s P/E is 88 percent below the 52.13x average, and its ROE is 7.38 percentage points below the 23.99% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.
What Makes Star Imaging and Path Lab Worth Watching in Diagnostic Services
- Scale: At Rs 125 Cr, its market capitalisation is smaller than Dr Lal PathLabs (Rs 32,511 Cr) and Thyrocare Technologies (Rs 7,873 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
- Sector drivers: Patient footfall, the test mix across pathology and radiology and tie ups with institutions and government bodies drive revenue and margins.
- Key risk: Diagnostic services are competitive and depend on referrals and test volumes, so lower footfall can affect earnings. Trading volumes in the stock are small.
Star Imaging and Path Lab Valuation: Is It Justified?
At a P/B ratio of 1.08, the market pays about Rs 1.08 for every rupee of book value, and the EPS (TTM) of Rs 11.05 is the earnings base behind the P/E. The stock trades about 53 percent below its 52-week high and about 56 percent above its 52-week low. The company does not currently show a dividend yield, so returns for shareholders depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Star Imaging and Path Lab and other Diagnostic Services sector stocks.
How to Track Star Imaging and Path Lab Before You Invest
Before deciding whether Star Imaging and Path Lab deserves its label as the best stock in its sector for your own portfolio, compare it directly against Diagnostic Services sector peers using the steps below.
- Open the Univest Screener and search for Star Imaging and Path Lab to view live price, valuation ratios, and peer comparisons within the Diagnostic Services sector.
- Compare its P/E, P/B, and ROE against other Diagnostic Services sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Star Imaging and Path Lab gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Diagnostic Services depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Star Imaging and Path Lab the best stock in its sector?
Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Star Imaging and Path Lab has a 16.61% ROE and trades at 6.49x P/E against a 59.59x Industry P/E. Against the 2 peers compared in this article, its ROE is below the 23.99% peer average and its P/E is below the 52.13x peer average. Its debt to equity ratio of 0.18 is above the 0.08 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.
What is the current share price of Star Imaging and Path Lab?
Ans. Star Imaging and Path Lab was trading at Rs 71.75 on the BSE as of 22 October 2026, and its 52-week range runs from Rs 46.00 to Rs 152.00. That leaves the share price 53 percent short of the 52-week high and 56 percent clear of the 52-week low. Its market capitalisation is Rs 125 Cr and its EPS (TTM) is Rs 11.05, which is the earnings figure behind the 6.49x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.
What sector does Star Imaging and Path Lab belong to?
Ans. Star Imaging and Path Lab is classified under the Diagnostic Services sector on Univest, and that group of listed companies is the reference point for the 59.59x Industry P/E used in this article. The 2 named peers compared here are Dr Lal PathLabs and Thyrocare Technologies, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Diagnostic Services sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.
How does Star Imaging and Path Lab compare to its sector peers on P/E?
Ans. Star Imaging and Path Lab’s P/E of 6.49x is below the 52.13x average of the 2 named peers, with Dr Lal PathLabs at 59.51x and Thyrocare Technologies at 44.76x. It also sits below the 59.59x Industry P/E, which is the benchmark for the wider Diagnostic Services sector. A P/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 1.08 gives one more view of how the market values its book value.
What is Star Imaging and Path Lab’s return on equity?
Ans. Star Imaging and Path Lab reported a return on equity of 16.61%, which is below the 23.99% average of its named peers, with Dr Lal PathLabs at 20.13% and Thyrocare Technologies at 27.85%. ROE shows how much profit a company generates on every rupee of shareholders’ equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.18 against a peer average of 0.08. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.
Should I invest in Star Imaging and Path Lab based on its sector position?
Ans. Sector position is only one input into an investment decision. Star Imaging and Path Lab has a 16.61% ROE and a 6.49x P/E, which make it worth researching further, and its dividend yield is 0.00%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.
